Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SENSORCAINE vs MARCAINE HYDROCHLORIDE PRESERVATIVE FREE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
SENSORCAINE (bupivacaine) is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting depolarization and propagation of action potentials, resulting in reversible local anesthesia.
Bupivacaine blocks sodium ion channels in nerve cell membranes, preventing the generation and conduction of nerve impulses, resulting in local anesthesia.
Local anesthesia by infiltration,Peripheral nerve block,Epidural and spinal anesthesia,Caudal anesthesia,Sympathetic nerve block
Local anesthesia for surgical procedures,Obstetric anesthesia,Diagnostic and therapeutic nerve blocks
Epidural or caudal block: 15-30 m L of 0.5% to 1% solution (75-150 mg) every 2-4 hours as needed. Maximum single dose: 225 mg.
Local infiltration: up to 30 m L of 0.5% (150 mg) per dose. Peripheral nerve block: 30-40 m L of 0.5% (150-200 mg). Epidural: 15-20 m L of 0.5% (75-100 mg). Maximum single dose: 2.5 mg/kg (225 mg for 90 kg). Repeat doses after 3 hours, max 400 mg/24h.
The terminal elimination half-life of bupivacaine is approximately 2.7 hours in adults (range 1.5–5.5 hours). In neonates, the half-life is significantly prolonged (~8–12 hours) due to immature hepatic function, leading to an increased risk of toxicity.
Terminal elimination half-life in adults: 2.7 ± 1.2 hours (range 1.5-5.5 hours). In neonates, half-life is prolonged to approximately 8.1 ± 8.2 hours due to immature hepatic and renal function.
No dose adjustment required for mild to moderate impairment (GFR ≥30 m L/min). Severe impairment (GFR <30 m L/min): reduce dose by 50% and monitor for CNS toxicity.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reduced doses and extended intervals due to potential accumulation; monitor for toxicity.
SENSORCAINE with epinephrine is not recommended for obstetrical use (paracervical block) as it can cause fetal bradycardia and death. All local anesthetics, including bupivacaine, may cause methemoglobinemia.
Sensorcaine (bupivacaine) is classified as FDA Pregnancy Category C. In the first trimester, there is a potential risk of developmental abnormalities based on animal studies showing increased fetal resorptions and delayed ossification at high doses. During the second and third trimesters, no significant teratogenic effects have been reported in humans, but the drug may cause fetal bradycardia and metabolic acidosis due to increased placental transfer near term. Use only if clearly needed.
FDA Pregnancy Category C. No adequate well-controlled studies in pregnant women. Bupivacaine crosses placenta. First trimester: No evidence of teratogenicity in animal studies, but risk cannot be excluded. Second/third trimester: Potential for fetal bradycardia, acidosis, and central nervous system depression if high doses or accidental intravascular injection occurs. Use only if clearly needed.
Sensorcaine (bupivacaine) is a long-acting amide local anesthetic. Due to high cardiac toxicity, use low concentrations (0.25-0.5%) for peripheral nerve blocks and avoid intravascular injection. Maximum dose: 2 mg/kg (with epinephrine 3 mg/kg). Not recommended for obstetrical paracervical block. Use with caution in hepatic impairment. Levobupivacaine is the S-enantiomer with lower cardiotoxicity.
Marca ine Hydrochloride Preservative Free (bupivacaine) is a long-acting amide local anesthetic with a slow onset. It is contraindicated for intravenous regional anesthesia (Bier block) due to risk of cardiotoxicity. For epidural use, a test dose of 2-3 m L with epinephrine helps detect intravascular injection (increased heart rate). Maximum safe dose: 2 mg/kg alone, 3 mg/kg with epinephrine. Use with caution in patients with hepatic impairment or pseudocholinesterase deficiency. For obstetrics, avoid paracervical block in pregnancy due to fetal bradycardia.
No interactions on record
No interactions on record
SENSORCAINE and MARCAINE HYDROCHLORIDE PRESERVATIVE FREE are distinct pharmacological agents. SENSORCAINE belongs to the Local Anesthetic class and is primarily used for Local anesthesia by infiltrationPeripheral nerve blockEpidural and spinal anesthesiaCaudal anesthesiaSympathetic nerve block. MARCAINE HYDROCHLORIDE PRESERVATIVE FREE belongs to the Local Anesthetic class and is primarily used for Local anesthesia for surgical proceduresObstetric anesthesiaDiagnostic and therapeutic nerve blocks. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. SENSORCAINE carries a safety status of Category C, whereas MARCAINE HYDROCHLORIDE PRESERVATIVE FREE safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily metabolized by the liver via conjugation with glucuronic acid; also hydrolyzed by plasma pseudocholinesterase to form pipecolylxylidine (PPX), the major metabolite.
Metabolized primarily in the liver via N-dealkylation and conjugation with glucuronic acid; enzyme CYP3A4 involved.
SENSORCAINE (bupivacaine) is primarily metabolized in the liver via conjugation with glucuronic acid and undergoes hepatic dealkylation. Approximately 6% of the drug is excreted unchanged in the urine. The majority of the dose (about 95%) is excreted as metabolites in the urine (<10% unchanged) and the remainder in feces via biliary elimination.
Primarily hepatic metabolism to 2,6-pipecoloxylidide (PPX) and subsequent renal excretion. Renal excretion of unchanged bupivacaine accounts for approximately 5-10% of the dose. The remainder is eliminated as metabolites (PPX and others) in urine. Fecal excretion is negligible.
Bupivacaine is highly protein-bound (~95%) primarily to alpha-1-acid glycoprotein (AAG) and to a lesser extent albumin. Binding is concentration-dependent and saturable; increased free fraction in conditions with low AAG (e.g., pregnancy, neonates, critical illness).
Approximately 95% bound to plasma proteins, primarily to alpha-1-acid glycoprotein (AAG). Binding is concentration-dependent, with lower binding at high concentrations due to saturation of AAG. Also binds to albumin to a lesser extent.
Volume of distribution (Vd) at steady state is approximately 0.6–1.0 L/kg in adults (range 50–100 L). The large Vd reflects extensive tissue distribution, with rapid uptake into well-perfused organs (brain, heart, liver, kidneys).
Apparent volume of distribution (Vd_ss): approximately 1.0 L/kg (range 0.6-1.5 L/kg). This large Vd indicates extensive tissue distribution, particularly into well-perfused organs and adipose tissue.
Bioavailability after epidural administration is approximately 98% due to extensive vascular absorption from the epidural space. For intravenous administration, bioavailability is 100%. Oral bioavailability is low (~30–40%) due to extensive first-pass metabolism.
Intravenous: 100%. Epidural: near 100% after absorption into systemic circulation. Peripheral nerve blocks: systemic bioavailability is near 100% after absorption. Oral: negligible (<10%) due to extensive first-pass hepatic metabolism.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and monitor. Child-Pugh Class C: Avoid use or use with extreme caution; consider alternative agent.
Neonates and infants: 0.5-1 mg/kg by infiltration or nerve block, maximum 4 mg/kg/day. Children: 1-2 mg/kg per dose, maximum 5 mg/kg/day.
Weight-based: 0.5-2.5 mg/kg for infiltration and nerve blocks. Maximum single dose: 2.5 mg/kg. Do not exceed concentrations of 0.25% for children under 12. For epidural: 1-2 mg/kg bolus followed by 0.1-0.25 mg/kg/h infusion, not to exceed 1 mg/kg in 4 hours.
Reduce initial dose by 30-50% due to reduced clearance and increased sensitivity; titrate carefully.
Reduce initial doses by 20-30% due to decreased hepatic clearance and increased sensitivity. Use lower concentrations (0.25%) and smallest effective volume. Monitor for hypotension and bradycardia. Maximum single dose: 2 mg/kg.
Risk of cardiac arrest and death with use as an epidural anesthetic for obstetrical paracervical block. Bupivacaine should not be injected rapidly or in large doses due to risk of systemic toxicity and cardiac arrest.
No significant food interactions. Avoid alcohol consumption as it may increase the risk of central nervous system depression.
No significant food interactions known. Avoid alcohol consumption for at least 24 hours after administration, as it may increase the risk of central nervous system depression or additive effects.
Bupivacaine is excreted in human breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.3. Although it is considered compatible with breastfeeding, caution is advised due to the potential for cumulative local anesthetic effects in the infant, especially with repeated doses. Monitor the infant for drowsiness and feeding difficulties.
Bupivacaine is excreted into breast milk in small amounts. Reported M/P ratio of bupivacaine is approximately 0.3-0.4. The relative infant dose is estimated at <2% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for signs of local anesthetic toxicity (e.g., drowsiness, poor feeding) if prolonged or high-dose maternal exposure.
No specific dosing adjustments are recommended for bupivacaine during pregnancy. However, reduced protein binding and increased volume of distribution in pregnancy may lower peak plasma concentrations. Clinicians should use the lowest effective dose and highest concentration to minimize total dose, especially for epidural or regional blocks. Monitor for prolonged effect due to decreased clearance.
No standard dosing adjustments for bupivacaine in pregnancy, but dose requirements may be reduced due to increased sensitivity to local anesthetics and engorged epidural veins. Use lowest effective dose. Epidural test dose with epinephrine (15 mcg) may be used to detect intravascular injection, but caution in hypertensive disorders. Consider reduced concentration (e.g., 0.125% vs 0.25%) for labor analgesia.
You may experience temporary numbness or loss of sensation in the injected area.,Avoid driving or operating machinery until sensation fully returns.,Report any signs of allergic reaction, such as rash, swelling, or difficulty breathing.,Do not rub or massage the injection site to prevent spread of the drug.,Contact your healthcare provider if numbness persists beyond the expected duration.
Inform your doctor if you have liver disease, low blood pressure, or a history of allergic reactions to local anesthetics.,You may experience temporary numbness or loss of sensation and motor function in the treated area; avoid activities that require alertness until sensation returns.,Do not drive or operate machinery for at least 24 hours after receiving this medication.,Contact your healthcare provider immediately if you experience difficulty breathing, chest tightness, irregular heartbeat, seizures, or severe headache after injection.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor.,Store this medication at room temperature away from light and moisture; do not freeze.